Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2022

01-01-2022 | Pneumonia | Clinical Vignette

Acute Hypoxemic Respiratory Failure with High Clinical Suspicion of COVID-19 Despite Negative PCR: a Case for Empiric Corticosteroids and Role of Serum Antibody in Diagnosis

Authors: Vannesa Cederstrom, MD, Heidi Erickson, MD, James Leatherman, MD

Published in: Journal of General Internal Medicine | Issue 1/2022

Login to get access

Excerpt

HN cis a 39-year-old healthy male who worked as an essential worker in a healthcare setting. He first presented to clinic in November 2020 with 3 days of fatigue, myalgias, and chills after a high-risk encounter with a confirmed COVID-19-positive person. Nasopharyngeal samples for COVID-19 and influenza by PCR were collected and both were negative. Eight days after symptom onset, he returned to clinic with additional symptoms of dry cough and diarrhea. Again, his COVID-19 and influenza PCRs were negative. Ten days after symptom onset, the patient was admitted from clinic, at which time his exam was notable for decreased breath sounds at the bases and he had hypoxemia requiring 2 LPM of supplemental oxygen. A chest x-ray showed bilateral patchy infiltrates (Fig. 1). On admission, he had additional symptoms of shortness of breath, sore throat, nausea, and headache. Initial work-up was highly suggestive of COVID-19 pneumonia, with elevated inflammatory markers (D-dimer 317 ng/ml, ferritin 3,562 ng/ml, CRP > 300 mg/l), a white blood cell count of 8.1 k/cmm with normal differential, and a CT pulmonary angiogram that showed bilateral extensive patchy ground glass opacities without pulmonary emboli (Fig. 1). Because of high clinical suspicion of COVID-19, he was given a dose of dexamethasone, but the COVID-19 nasopharyngeal PCR collected in the emergency department was again negative. Pulmonology and infectious disease were consulted. Due to three negative COVID-19 PCRs, a work-up for alternative diagnoses was pursued, with the differential diagnosis including atypical bacterial pneumonia, viral pneumonia, eosinophilic pneumonia, heart failure, acute interstitial pneumonitis, and cryptogenic organizing pneumonia. While awaiting these results, the patient was started on azithromycin and ceftriaxone, but no further corticosteroids were given. Over the next 3 days of hospitalization, his shortness of breath and dry cough worsened. Fourteen days after symptom onset, his oxygen requirement increased from 2 to 5 LPM and a repeat chest x-ray showed worsening bilateral opacities. Thus far, the patient’s work-up was notable for a normal transthoracic echocardiogram, low procalcitonin, negative HIV, negative legionella PCR, negative respiratory viral panel, and a third negative influenza PCR. Due to lack of a diagnosis and worsening respiratory status, he underwent bronchoscopy with bronchoalveolar lavage (BAL) 15 days after symptom onset. On the day of bronchoscopy, his serum COVID-19 antibody that had been collected the previous day was reported to be positive. Although we were unable to be certain as to the chronicity of his infection, the positive serum antibody was believed to support a presumptive diagnosis of severe COVID-19 pneumonia and he was treated with corticosteroids. Cultures and stains of the BAL were negative for bacteria, fungi, mycobacteria, and pneumocystis. However, a PCR for SARS-COV-2 on the BAL came back positive, confirming a diagnosis of COVID-19 pneumonia. Corticosteroids were continued as dexamethasone 6 mg/day for 10 days and he was also given remdesivir. Over the next few days, he rapidly improved and was discharged home on hospital day 11, 21 days after symptom onset.
Literature
1.
go back to reference RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384 (8):693-704.CrossRef RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384 (8):693-704.CrossRef
2.
go back to reference Van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020; 24:1-22.CrossRef Van Paassen J, Vos JS, Hoekstra EM, et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care. 2020; 24:1-22.CrossRef
3.
go back to reference Sterne JAC, Murthy S, Diaz J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. JAMA. 2020; 324 (13): 1330-1341.CrossRef Sterne JAC, Murthy S, Diaz J, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis. JAMA. 2020; 324 (13): 1330-1341.CrossRef
5.
go back to reference Tahamtan A, Abdollah A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Exp Rev Mol Diagn. 2020; 20(5): 453-454.CrossRef Tahamtan A, Abdollah A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Exp Rev Mol Diagn. 2020; 20(5): 453-454.CrossRef
7.
go back to reference Miller TE, et al. Clinical sensitivity and interpretation of PCR and serological COVID‐19 diagnostics for patients presenting to the hospital. FASEB J. 2020; 00:1-8. Miller TE, et al. Clinical sensitivity and interpretation of PCR and serological COVID‐19 diagnostics for patients presenting to the hospital. FASEB J. 2020; 00:1-8.
8.
go back to reference Chen H, et al. The role of serum specific-SARS-CoV-2 antibody in COVID-19 patients. Int Immunopharmacol. 2021; 91: 107325. Chen H, et al. The role of serum specific-SARS-CoV-2 antibody in COVID-19 patients. Int Immunopharmacol. 2021; 91: 107325.
9.
go back to reference Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020; 370:m3325.CrossRef Watson J, Richter A, Deeks J. Testing for SARS-CoV-2 antibodies. BMJ. 2020; 370:m3325.CrossRef
10.
go back to reference Villar J, Ferrando C, Martinez, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomized controlled trial. Lancet Respir Med. 2020; 8(3): 267-276.CrossRef Villar J, Ferrando C, Martinez, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicenter, randomized controlled trial. Lancet Respir Med. 2020; 8(3): 267-276.CrossRef
11.
go back to reference Chen R-C, Tang X-P, Tan S-Y, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129 (6): 1441-1452.CrossRef Chen R-C, Tang X-P, Tan S-Y, et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest. 2006; 129 (6): 1441-1452.CrossRef
Metadata
Title
Acute Hypoxemic Respiratory Failure with High Clinical Suspicion of COVID-19 Despite Negative PCR: a Case for Empiric Corticosteroids and Role of Serum Antibody in Diagnosis
Authors
Vannesa Cederstrom, MD
Heidi Erickson, MD
James Leatherman, MD
Publication date
01-01-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 1/2022
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07177-7

Other articles of this Issue 1/2022

Journal of General Internal Medicine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.